Citi Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Bristol-Myers Squibb (BMY) Pressured on Market Open, Down 6.6%
October 22, 2018 9:31 AM EDTBristol-Myers Squibb (NYSE: BMY) Pressured on Market Open, Down 6.6%
... MoreBristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -067 Clinical Trial for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)
October 22, 2018 6:00 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial the longest follow-up to date which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 months,... More
